Ophthalmology is one of the most trial-dense specialties in medicine — retina especially, where anti-VEGF successors, gene therapies, and geographic atrophy treatments keep sponsors hunting for sites with real patient volume. For a private eye care practice, becoming a site offers diversified revenue, early access to therapies, and standing with referring optometry practices. It also imports a second business into your building. Here's the clear-eyed version.
What sponsors actually screen for
Sponsors pick sites that enroll and document. Your pitch is concrete: disease-population counts pulled from your EHR (how many wet AMD patients on active treatment? how many geographic atrophy diagnoses?), imaging capability (certified-grade OCT, photographers who can pass reading-center qualification), physical space for monitors and storage, and — above all — a named coordinator. A practice with modest volume and a crisp coordinator outperforms a huge practice where research is everyone's third job.
The coordinator is the whole ballgame
Every trial runs on its coordinator: screening logs, visit scheduling inside strict protocol windows, case report forms, query resolution, drug accountability, regulatory binders, monitor visits. Underestimating this role is the classic first-site failure — the practice signs a study, assigns it to an already-full technician, misses windows, and earns a reputation problem with the sponsor's CRO that follows them. Plan the staffing before the first contract: a dedicated or majority-time coordinator, plus administrative support for the scheduling, reminder calls, travel stipends, and document chasing that surround every subject visit. That surrounding layer — distinct from the regulated coordinator duties — is work many research practices route to a trained eye care virtual assistant at a flat $10/hour, keeping the coordinator inside the protocol where their training matters.
Start with the right studies
First sites should favor: sponsors with strong CRO support, protocols adjacent to care you already deliver (an injection-clinic practice absorbs a retina trial's rhythm naturally — see our injection workflow guide), and realistic enrollment targets you can hit from your own panel. Registry and post-market studies are gentler on-ramps than pivotal trials. Say no to protocols whose visit schedules your clinic can't absorb; a failed study costs more reputation than no study.
The honest economics
Per-subject payments look attractive until you cost the hours — startup and regulatory time, screening failures (often compensated thinly), coordinator salary, physician oversight. Most sites report research reaching sustainable profitability in year two or three, once multiple concurrent studies share fixed costs. Model it that way from the start: research is a product line with a ramp, not found money. The non-financial returns — therapeutic access for your patients, differentiation in the referral market, intellectual life for physicians — arrive earlier and, for many ophthalmology groups, justify the ramp on their own.
.png)
.png)
.png)
